• David Moreno-Ajona, Jan Hoffmann, and Simon Akerman.
• Headache Group, Institute of Psychology, Psychiatry and Neuroscience, Wolfson Centre for Age-Related Diseases, King's College London, London, SE5 9PJ, UK.
• Curr Pain Headache Rep. 2022 Mar 1; 26 (3): 259265259-265.

Purpose Of ReviewHistorically, therapies for migraine have generally involved pharmacological treatments using non-selective or selective analgesics and preventive treatments. However, for many patients these treatments are not effective, while others prefer to use non-pharmacological-based therapies. To fill this need, over the last 15 years, neuromodulatory devices have entered the market for migraine treatment. Here, we will review the most recent findings for the use of these devices in the treatment of migraine.Recent FindingsNon-invasive vagus nerve stimulation and spring-pulse transcranial magnetic stimulation are both cleared for the treatment of migraine, supported by preclinical studies that validate efficacy and mechanism of action, and complemented with clinical trial data. Other options also authorized for use include transcutaneous supraorbital nerve stimulation and remote electrical neuromodulation. Various options are available to treat migraine using authorized neuromodulatory devices. These data support their efficacy in the treatment of episodic migraine, although further studies are necessary to elucidate their mechanism of action and to provide rigor to clinical trial data.© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

23 keywords...

hide…